Fig. 5. Addition of HSA to virus preparation before dialysis does not compromise transduction enhancement.

AAV8/luc viruses purified either from CsCl or column were mixed with 1% of 25% HSA, and then applied for dialysis against PBS. After dialysis, AAV viruses were frozen; two days later, the in vivo transduction assay was performed. For liver transduction, 1×10¹⁰ particles of AAV/luc were administered via retro-orbital injection; the imaging was taken at day 3 after AAV injection for 5 mice (a). For muscle transduction, 1×10⁹ particles of AAV/luc were used; imaging was performed at day 7 post injection for 4 mice (a). Face up: left leg-HSA, right leg-PBS. Quantitation of imaging (b) was also performed.